Abstract
Background Post-colonoscopy colorectal cancers (PCCRCs) pose a challenge in clinical practice. PCCRCs occur due to a combination of procedural and biological causes. Specific features of lesions may contribute for this. In a nested case-control study, we compared clinical and molecular features of PCCRCs and detected CRCs (DCRCs).
Methods PCCRCs were defined according to the WEO 2018 classification, as cancers occurring after a complete index colonoscopy, which excluded CRC. CRCs in patients without colonoscopy or with colonoscopy >10 years before were defined as DCRCs. Whole genome chromosomal copy number changes and mutation status of genes commonly affected in CRC (including APC, KRAS, BRAF, FBXW7, PIK3CA, NRAS, SMAD4 and TP53) were examined by low-coverage WGS and targeted sequencing, respectively. MSI and CIMP status were also determined.
Results In total, 122 PCCRCs and 98 DCRCs with high quality DNA were examined. PCCRCs were more often located proximally in the colon (p<0.001), non-polypoid appearing (p=0.004), early stage (p=0.009), and poorly differentiated (p=0.006). PCCRCs showed similar patterns of DNA copy number changes typical of CRC, although significantly less 18q loss (FDR <0.2), compared to DCRCs. No significant differences in mutations were detected between PCCRCs and DCRCs. PCCRCs were more commonly CIMP-high (p=0.014) and MSI (p=0.029). After correction for tumour location, the only molecular difference between PCCRCs and DCRCs that remained significant was less frequent loss of 18q chromosome in PCCRCs (p=0.005).
Conclusion Although PCCRCs show molecular characteristics that are common to the canonical CIN, MSI and hypermethylation pathways, molecular features associated with the sessile serrated lesions (SSLs) and non-polypoid colorectal neoplasms (CRNs) are more commonly seen in PCCRCs than in DCRCs. This and the clinical features observed in PCCRCs support the hypothesis that sessile serrated lesions and non-polypoid CRNs are contributors to the development of these cancers. In order to further reduce the occurrence of PCCRCs, the focus should be directed at improving the detection, determination and endoscopic removal of these non-polypoid CRN and SSLs.
Clinical Trial Registration NTR3093 in the Dutch trial register (www.trialregister.nl)
Competing Interest Statement
AM received funding from the Dutch Cancer Society, from the Dutch Organization for Health Research and Development, from Pentax Europe GmBH. AM has given scientific advice to Kyowa Kirin, Bayer, and Takeda. BC has several patents pending. All other authors had no other disclosures.
Clinical Trial
NTR3093 in the Dutch trial register (www.trialregister.nl)
Funding Statement
RB and CLC received an unrestricted educational grant from Pentax Medical BV. BY contributed to the manuscript with support of the Dutch Cancer Society (Grant No. KWF 2015-7882).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Medical Ethical Committee of the Maastricht University Medical Centre, which waived the need for informed consent. The study is registered as study NTR3093 in the Dutch trial register (www.trialregister.nl). The study was performed in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The study is registered as study NTR3093 in the Dutch trial register (www.trialregister.nl)
Data Availability
The sequencing data used in the present study is available in the European Genomes and phenomes Archive (ega-archive.org), with provisory number EGAS00001004686.
Abbreviations
- 95%CI
- 95% confidence interval
- CIMP
- CpG Island Methylator Phenotype
- CRC
- Colorectal cancer
- CIN
- Chromosomal Instability
- CRN
- Colorectal neoplasm
- DCRC
- Detected CRC
- FFPE
- Formalin-fixed, paraffin-embedded
- MSI
- Microsatellite instability
- OR
- Odds ratio
- PCCRC
- Post-colonoscopy colorectal cancer
- SSL
- Sessile serrated lesion
- WGS
- Whole genome sequencing